Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.35 | 4.91% | 0.11 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.91% | |
| Crossed Above 20 DMA | Bullish | 4.91% | |
| Crossed Above 200 DMA | Bullish | 4.91% | |
| MACD Bullish Signal Line Cross | Bullish | 4.91% | |
| New Uptrend | Bullish | 4.91% | |
| Pocket Pivot | Bullish Swing Setup | 4.91% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 22 hours ago |
| Rose Above 50 DMA | about 22 hours ago |
| Up 5% | about 22 hours ago |
| Up 3% | about 22 hours ago |
| Down 5% | 1 day ago |
Get a Trading Assistant
- Earnings date: 05/03/2024
XTL Biopharmaceuticals Ltd. Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Pharmacy Clinical Development Medication Pharmaceutical Products FDA Schizophrenia Multiple Myeloma Orphan Drug Anemia Hepatitis C Drug Design Antipsychotic Erythropoietin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.9897 |
| 52 Week Low | 0.75 |
| Average Volume | 47,640 |
| 200-Day Moving Average | 2.17 |
| 50-Day Moving Average | 2.33 |
| 20-Day Moving Average | 1.98 |
| 10-Day Moving Average | 1.82 |
| Average True Range | 0.26 |
| RSI (14) | 57.81 |
| ADX | 34.15 |
| +DI | 32.67 |
| -DI | 20.39 |
| Chandelier Exit (Long, 3 ATRs) | 1.73 |
| Chandelier Exit (Short, 3 ATRs) | 2.06 |
| Upper Bollinger Bands | 2.54 |
| Lower Bollinger Band | 1.43 |
| Percent B (%b) | 0.83 |
| BandWidth | 55.48 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.17 |
| MACD Histogram | 0.0621 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.77 | ||||
| Resistance 3 (R3) | 2.73 | 2.56 | 2.70 | ||
| Resistance 2 (R2) | 2.56 | 2.45 | 2.58 | 2.68 | |
| Resistance 1 (R1) | 2.45 | 2.38 | 2.51 | 2.49 | 2.65 |
| Pivot Point | 2.28 | 2.28 | 2.30 | 2.29 | 2.28 |
| Support 1 (S1) | 2.17 | 2.17 | 2.22 | 2.21 | 2.05 |
| Support 2 (S2) | 2.00 | 2.10 | 2.01 | 2.02 | |
| Support 3 (S3) | 1.89 | 2.00 | 2.00 | ||
| Support 4 (S4) | 1.93 |
